Compare Amgen, Inc. (AMGN) vs Schlumberger NV (SLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Schlumberger NV — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Schlumberger NV trades at $48.2 (market cap $71.40B). The key difference: Amgen, Inc. is far larger — about 2.7× Schlumberger NV's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | SLB | |
|---|---|---|
Market Cap | $196.12B | $71.40B |
Sector | Health | Energy |
52-Week High | $388.16 | $58.01 |
52-Week Low | $271.18 | $31.72 |
Enterprise Value | $241.41B | $79.62B |
Dividend Yield | 2.77% | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SLB trades at $47.76, up 1.1% with a bullish technical signal despite recent volatility. The company reported Q1 2026 EPS of $0.52, beating expectations, and maintains strong cash flow from operations at $6.49B. Recent news highlights a seven-year Kuwait contract expansion and digital marketplace launch, supporting growth prospects amid oil price fluctuations.
Outlook: Analyst consensus is bullish with an $62.14 price target (30% upside). Risks include oil price sensitivity and Middle East exposure, but digital transformation and contract wins provide stability. Valuation metrics (P/E 21.04, P/S 1.95) appear reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
